MedicalResearch.com Interview with:
Ron B. Mitchell, MD
Professor of Otolaryngology and Pediatrics
William Beckner Distinguished Chair in Otolaryngology
Chief of Pediatric Otolaryngology
UT Southwestern and Children's Medical Center Dallas
ENT Clinic Dallas, TX 75207
Medical Research: What is the background for this study? What are the main findings?
Dr. Mitchell: The “gold standard” for the diagnosis of and quantification of obstructive sleep apnea (OSA) is polysomnography (PSG or a ‘sleep study’). However, the majorities of T&A procedures are done without PSG and are based on a clinical diagnosis. This is because PSG is expensive, requires overnight observation and is often unavailable. It is important to diagnose and quantify OSA as it allows for surgical planning and predicts the need and type of treatment after surgery.
We used data from the Childhood Adenotonsillectomy (CHAT) study; a large multicenter
trial (RCT), to look at the ability of clinical parameters to predict the severity of obstructive sleep apnea in children scheduled for a T&A.
The main findings of the study are that certain clinical parameters such as obesity and African American race as well as high scores on certain validated questionnaires (such as the pediatric sleep questionnaire- PSQ) are associated, but cannot predict OSA severity. PSG remains the only way to measure objectively the severity of OSA.
MedicalResearch.com Interview with:
Rania Mekary, MS, Ph.D.
Harvard School of Public Health
Nutrition Department
Boston, Ma 02115
Medical Research: What is the background for this study? What are the main findings?
Dr. Mekar: Findings on weight training and waist circumference (WC) change have been controversial. Moreover, a lot of people focus on aerobic and only aerobic workout... They are not to be blamed because aerobic workout (e.g. jogging) relies mostly on fat as a source of energy while anaerobic workout (e.g. resistance) relies mostly on carbohydrates. Our study, however, showed that resistance training over the long-term was the most inversely associated with waistline change (aka abdominal fat), even more than aerobic exercise. We also justified physiologically why it is the case... It has to do with the greater Excess Post-exercise Oxygen Consumption (EPOC) as compared with aerobic training and also to the muscle adaptation and its increase in mitochondria which leads to more lipid oxidation upon engaging in anaerobic workout over the long-term.
MedicalResearch.com Interview with:
Dr. Johan Sundström MD PhD
Department of Medical Sciences &
Uppsala Clinical Research Center
Uppsala University Uppsala, Sweden.
Medical Research: What is the background for this study? What are the main findings?
Dr. Sundström: High blood pressure is the most important risk factor for premature death globally. The number of people with hypertension is increasing, with one billion people currently affected worldwide. Most of these have mild hypertension (a systolic blood pressure of 140 to 159 mm Hg and/or a diastolic blood pressure of 90 to 99 mm Hg) and no previous cardiovascular disease. The optimal management of this large group is uncertain, as no single trial of blood pressure lowering has provided clear evidence of treatment benefits for such persons.
In this systematic review and meta-analysis of 13 randomized controlled trials including more than 15000 people with mild hypertension and without previous known cardiovascular disease, blood pressure-lowering drug therapy decreased strokes by 28%, cardiovascular deaths by 25%, and total deaths by 22%. Achieved blood pressure reduction and numbers of events were small.
MedicalResearch.com Interview with:
Ania Z. Kielar, MD, FRCPC
Department of Radiology at the University of Ottawa
The Ottawa Hospital, Ottawa, Ontario,Canada
Medical Research: What is the background for this study? What are the main findings?
Dr. Kielar: One of the goals of imaging is to provide homogeneous and consistent, high-quality care for patients using available equipment. In our hospital system, we had two separate hospitals that merged to form one teaching centre over 15 years ago. Most processes and protocols are same between the two hospital sites as a result of having the same administration and the same University affiliation. Also, the same residents and staff rotate through the emergency departments and radiology departments at both hospitals. One variable that persists is the location of the CT scanner. At one center a space was created to place a CT scanner in the Emergency Department. At the other site, the CT scanner is in the radiology department. For non-trauma cases, we wanted to see if the difference in distance of the scanner with respect to the emergency department location, has a role in the time required to obtain CT scan from the time it is requested ,as well as the time to final patient disposition. We defined final patient disposition to include admission, subspecialty consultation or discharge home.
Medical Research: What are the main findings?
Dr. Kielar: We found that there was a statistically significant difference in the time between requested CT and time to completion of the CT between the two hospital sites. It was faster when the CT scanner was located in the emergency department. This was in the range of 16 minutes ,which is longer than simply the time required to walk over (and back) to the the CT scanner from the emergency department.
We also found a statistically significant difference in the time of the final patient disposition. Of note, there was no statistically significant difference noted in the time to obtain a CT scan as well as the preliminary radiology interpretation for patients with hyperacute conditions such as suspected abdominal aortic aneurysm rupture, regardless of the location of the CT scanner with respect to the ED.
MedicalResearch.com Interview with:
Dr. Ricardo Mosquera MD
Assistant professor of Pediatrics at The University of Texas Health Science Center at Houston Medical School
Clinic Director, UT Physicians, of the UTHealth Medical School.
Medical Research: What is the background for this study? What are the main findings?
Dr. Mosquera: There is not strong scientific evidence to support the use of medical homes. Medical homes have not been demonstrated to decrease adverse outcomes or costs in children. Such benefits are most likely for high-risk children with chronic illness. We conducted a rigorous and well designed, randomized controlled trial to determine if an enhanced medical home providing comprehensive care decreases serious illness (death, prolonged hospitalization>7 days, or intensive care unit admissions) and/or cost among high-risk chronically ill children.
An enhanced medical home decreased both adverse outcomes (decreased serious illness, hospitalizations, PICU admissions, and serious illness by ~50%) and cost (~$10.000 less per child/year).
MedicalResearch.com Interview with:
Justus V. Verhagen, Ph.D.
Associate Fellow, The John B. Pierce Laboratory
Associate Professor, Dept. Neurobiology,
Yale School Of Medicine
New Haven, CT 06519
Medical Research: What is the background for this study?
Dr. Verhagen: The study explores how the part of the brain that encodes odors (the Olfactory Bulb, OB) works. It is much studied, but much remains to be learned about the Olfactory Bulb.
It used to be thought that odors were encoded by spatial patterns of activity across the Olfactory Bulb alone. Due to advances in the resolution in imaging, it has become clear that odor coding is a highly dynamic process. We learned that after each sniff a pattern of activity evolves across the Olfactory Bulb, some areas activating sooner, some later. This suggested that the odor code is a spatial AND a temporal map, in other words, more like playing a brief movie than showing a brief picture after each sniff.
We tested whether this was true by using a relatively new method called “Optogenetics”, which allows us to accurately control the activity across the Olfactory Bulb.
MedicalResearch.com Interview with: Giovanni Filardo, PhD, MPH Director of Epidemiology, Baylor Scott & White Health, Dallas, TX The Bradley Family Endowed Chair in Cardiovascular Epidemiology, Baylor University Medical Center Director of Cardiovascular Epidemiology, The Heart Hospital Baylor, Plano, TX Research Associate Professor of Statistics, Southern Methodist University, Dallas, TX Medical Research: What should clinicians and patients take away...
MedicalResearch.com Interview with:
Dr. Anne McCartt PhD
Senior Vice President, Research
Insurance Institute for Highway Safety
Arlington, Virginia
Medical Research: What is the background for this study? What are the main findings?
Dr. McCartt: Motor vehicle crashes are a significant public health problem in the U.S., and that’s especially true for teenagers. Teen drivers have crash rates three times those of drivers 20 and older per mile driven. Immaturity leads to speeding and other risky habits, and inexperience means teens often don’t recognize or know how to respond to hazards.
The type of vehicle a teenager drives has a big effect on the degree of risk. Nevertheless, the main finding of our study is that many teenagers are driving – and dying in – the least protective types of vehicles. Nearly 30 percent of drivers ages 15-17 who died in highway crashes during 2008-12 were driving mini or small cars. Eight-two percent of the teenagers were driving vehicles that were at least 6 years old, and nearly half were driving vehicles that were at least 11 years old. Small cars are problem because they don’t afford as much crash protection as bigger, heavier vehicles. Older vehicles are less likely to have the best crash test ratings, and usually lack electronic stability control (ESC) or side airbags as standard features, despite the proven effectiveness of these technologies.
Parents are obviously concerned about safety. In a separate survey we found that safety ranked highest among the reasons for choosing a particular vehicle. Most parents knew that a midsize or larger vehicle was safer than a small one, but their knowledge about which safety features to seek out wasn’t very current. When asked what safety features they insisted on for their teen driver, people most frequently mentioned frontal airbags and safety belts. Only 5 percent of respondents mentioned ESC.
MedicalResearch.com Interview with:
Michael Nadorff, PhD, Assistant professor
Mississippi State University
Starkville, Miss.
Medical Research: What is the background for this study? What are the main findings?
Dr. Nadorff: A growing literature has found that insomnia symptoms are associated with suicidal behavior, and several studies suggest that this relation may be independent of several different forms of psychopathology. However, little research has examined the role sleep disorders, such as insomnia, play in explaining why known risk factors, such as alcohol use, are associated with suicidal behavior. In our study, we examined whether insomnia symptoms explained a significant portion of the relation between alcohol symptoms and suicide risk. We found that for both men and women insomnia symptoms explained a significant amount of the variance in the relation between alcohol use and suicide risk.
MedicalResearch.com Interview with:
Turhan Canli, Ph.D.
Associate Professor, Psychology and Radiology
Director, SCAN (Social, Cognitive, and Affective Neuroscience) Center
Senior Fellow, Center for Medical Humanities, Compassionate Care, and Bioethics Stony Brook University Stony Brook, NY 11794
Medical Research: What is the background for this study? What are the main findings?
Response: I was struck by two aspects of major depression treatment.
First, that today's drug treatments are not much different from those used decades ago, with no real progress in treatment effectiveness. In severe cases of major depression, antidepressants may give some symptom relief, but for less severe cases, the effectiveness of antidepressants is not clinically relevant.
Second, recurrence rates remain stubbornly high: patients with diagnosed MDD have a lifetime recurrency rate of 50%. We are not treating depression; at best, we reduce symptoms.
MedicalResearch.com Interview with:
Elina Helander, PhD
Personal Health Informatics
Department of Signal Processing
Tampere University of Technology, Tampere, Finland
Medical Research: What is the background for this study? What are the main findings?
Dr. Helander: Frequent or at least regular self-weighing is a part of behavioral therapy in many weight programs. However, self-weighing frequency typically varies over time. We analyzed almost 3,000 weight observations from 40 overweight individuals that participated in a 1-year health promotion program. These individuals were instructed to weigh themselves daily but eventually had varying self-weighing frequencies. We examined how different self-weighing frequencies of the same individual were linked with weight changes.
We found that weight loss generally occurred during daily weighing. When there were longer breaks in self-weighing such as one month or more, there was a risk of weight gain. We also computed a theoretical minimum self-weighing frequency for having no weight gain that was 5.8 days in our study. That corresponds approximately weekly weighing.
MedicalResearch.com Interview with:
David Gerberry PhD
Assistant Professor
Department of Mathematics and Computer Science
Xavier University, Cincinnati, Ohio
Medical Research: What is the background for this study? What are the main findings?
Response: In an attempt to control the spread of HIV, governments in sub-Saharan Africa are considering providing antiretroviral drugs to people who do not have the virus but are at risk for becoming infected. Such drugs are known as pre-exposure prophylaxis, or PrEP. Given the cost of PrEP, an important question is how to maximize the impact of interventions given a fixed level of prevention resources.
A common strategy is to target resources to the individuals that are at the highest risk for infection. This group of people is often referred to as the "core group" and can be thought of as sex workers, clients of sex workers and other individuals that are at very high risk for infection. While targeting this core group is ideal and would result in the most cost-effectiveness interventions, being able to identify these individuals is difficult in practice and they are often unwilling to participate in the intervention; take pre-exposure prophylaxis or change their behavior for example. From a mathematical perspective it is also very difficult to quantify their increased level of risk. For example, is a sex worker at 5 times, 25 times, 100 times or 1000 times the risk for HIV infection? Without this quantification, it is impossible to estimate the cost-effectiveness of a targeted strategy.
In our work, we build an intervention strategy based on geographical targeting. This takes advantage of the fact that HIV incidence is much higher in certain geographical locations than others. Therefore, individuals in these areas are at increased risk for HIV infection. Most importantly, such an intervention is feasible because reliable data exists across much of sub-Saharan Africa for the severity of the HIV epidemic in different regions. To illustrate our ideas we used mathematical modeling to consider resource allocation in South Africa and found that targeting the provinces with highest HIV incidence would prevent 40% more infections than a plan that ignored geographic variation while using the same amount of resources.
MedicalResearch.com Interview with:
Leonard A. Mermel DO FACP, FIDSA, FSHEA
Professor of Medicine,
Warren Alpert Medical School of Brown University and Division of Infectious Diseases,
Rhode Island Hospital Providence, Rhode Island
Medical Research: What is the background for this study? What are the main findings?
Dr. Mermel: While talking to infectious diseases physicians some years ago in Israel, Greece, and Thailand, I learned that unlike my experiene here in the US, most of the bloodstream infections they see are far and away due to Gram-negative bacteria. So, a hypothesis was generated, namely that the likelihood of Gram-negative bacteremia compared to Gram-positive bacteremia was greater the closer to the equator. A writing group was formed, colleagues around the world graciously shared their data. The main finding is that in fact, we unequivocally found that the likelihood of Gram-negative, compared to Gram-positive bacteremia is more common closer to the equator. This difference was greatest during the warmer months of the year. We also found that the % GDP spent on healthcare in a given country is also associated with more Gram-negative than Gram-positive bacteremia. These findings may reflect differences in the human microbiome as one gets closer or farther from the equator as has been recently demonstrated, differences in survival of Gram-negative compared to Gram-positive bacteria under certain environmental conditions, and likely reflects differences in public health and other factors.
MedicalResearch.com Interview with:
Thomas Wisniewski MD
Lulu P. and David J. Levidow Professor of Neurology
Professor; Director Aging and Dementia
New York University School of Medicine
Dept. of Neurology, Psychiatry and Pathology
New York, NY 10016
Medical Research: What is the background for this study? What are the main findings?
Dr. Wisniewski: Chronic wasting disease (CWD) infects large numbers of deer and elk, with the potential to infect humans. Currently no prionosis has an effective treatment. This is a relatively new prion disease that has many similarities to bovine spongiform encephalopathy which spread to humans to produce new variant Creutzfeldt-Jakob disease. Chronic wasting disease is the most infectious prion disease to date; having the potential to spread by aerosol. Previously, we have demonstrated we could prevent transmission of prions in a proportion of susceptible mice with a mucosal vaccine. In the current study, white-tailed deer were orally inoculated with attenuated Salmonella expressing PrP, while control deer were orally inoculated with vehicle attenuated Salmonella. Once a mucosal response was established, the vaccinated animals were boosted orally and locally by application of polymerized recombinant PrP onto the tonsils and rectal mucosa. The vaccinated and control animals were then challenged orally with CWD-infected brain homogenate. Three years post CWD oral challenge all control deer developed clinical CWD (median survival 602 days), while among the vaccinated there was a significant prolongation of the incubation period (median survival 909 days; p=0.012 by Weibull regression analysis) and one deer has remained CWD free both clinically and by RAMALT and tonsil biopsies. This negative vaccinate has the highest titers of IgA in saliva and systemic IgG against PrP. Western blots showed that immunoglobulins from this vaccinate react to PrPCWD. We document the first partially successful vaccination for a prion disease in a species naturally at risk.
MedicalResearch.com Interview with:
Prof. Giovambattista Desideri
Università degli Studi dell'Aquila
Direttore UOC Geriatria e Lungodegenza Geriatrica
Scuola di Specializzazione in Geriatria
Scuola di Specializzazione in Medicina d'Emergenza-Urgenza
Medical Research: What is the background for this study? What are the main findings?
Dr. Desideri: Over the past decade, there has been an accumulating body of evidence that indicates that the consumption of cocoa flavanol-containing products can improve vascular function. Though much research has focused on the cardiovascular system, there is reason to believe that some of the benefits of cocoa flavanol consumption could extend also to the brain which is a heavily vascularized tissue that depends on regular blood flow to meet its metabolic demands. Thus, the current study tested the hypothesis that the regular inclusion of cocoa flavanols for 8 weeks could positively affect cognitive function in cognitively-intact older adults. The effects of cocoa flavanol ingestion on various cardiometabolic endpoints, including blood pressure and insulin sensitivity, were also evaluated given consistent evidence of positive effects of flavanols on these outcomes and the potentially influential role of these outcomes on cognitive function.
Medical Research: What are the main findings?
Dr. Desideri:The study enrolled 90 men and women aged 61-85 years with no evidence of cognitive dysfunction who were assigned to one of three flavanol groups, consuming a drink containing high (993 mg), intermediate ( 520 mg) or low (48 mg) amounts of cocoa flavanols every day for 8 weeks. Among those individuals who regularly consumed either the high-or intermediate-flavanol drinks, there were significant improvements in some measures of age-related cognitive dysfunction. In the high- and intermediate-flavanol groups, both systolic and diastolic blood pressures were reduced and insulin resistance was significantly improved. It is not yet fully understood how cocoa flavanols bring about improvements in cognitive function, but the study results suggest that the improvements in insulin resistance and blood pressure could be revealing.
MedicalResearch.com Interview with:
Ying Xu
Assistant Professor, Ph.D.
Department of Civil, Architectural and Environmental Engineering
University of Texas, Austin
Medical Research: What is the background for this study? What are the main findings?
Response: Phthalates have been widely used as plasticizers to enhance the flexibility of polyvinyl chloride (PVC) products. They are ubiquitous and persistent indoor pollutants and may result in profound and irreversible changes in the development of human reproductive tract.
In this study, we found that the emissions of phthalates and phthalate alternatives increase significantly with increasing temperature. We developed an emission model and validated the model via chamber experiments. Further analysis showed that, in infant sleep microenvironments, an increase in the temperature of mattress can cause a significant increase in emission of phthalates from the mattress cover and make the concentration in breathing zone about four times higher than that in the room, resulting in potentially high exposure. In residential homes, an increase in the temperature from 25 to 35 ºC can elevate the gas-phase concentration of phthalates by more than a factor of 10, but the total airborne concentration may not increase that much for less volatile compounds.
MedicalResearch.com Interview with:
Erik Gunderson, M.D., FASAM
Assistant Professor
Department of Psychiatry and Neurobehavioral Sciences and Department of Medicine University of Virginia
Principal Investigator of the study
Medical Research: What is the background for this study? What are the main findings?
Response: The ISTART/006 study was a randomized, multicenter, non-inferiority Phase 3 clinical trial designed to evaluate the efficacy of ZUBSOLV® (buprenorphine and naloxone) sublingual tablet (CIII) compared with generic buprenorphine tablets during induction and with Suboxone® film during stabilization of patients with opioid dependence. The co-primary endpoint was retention in treatment at day 3 (when patients began maintenance therapy with either ZUBSOLV or Suboxone film) and retention in treatment at day 15. Secondary endpoints included assessment of treatment effects on opioid withdrawal symptoms for ZUBSOLV versus Suboxone film via both the Clinical Opiate Withdrawal Scale (COWS) score and Subjective Opiate Withdrawal Scale (SOWS), and opioid cravings via the visual analogue scale (VAS).
758 patients participated in a two-day blinded induction phase randomized to ZUBSOLV or generic buprenorphine tablets, and on day 3 those taking the generic tablets were switched to Suboxone film for a 20-day open-label stabilization and early maintenance phase. At day 15, ZUBSOLV patients switched to Suboxone film and those taking Suboxone film switched to ZUBSOLV.
Please note ZUBSOLV currently is not indicated for induction treatment. In October 2014, Orexo submitted a sNDA to the FDA for that indication.
We found ZUBSOLV demonstrated comparable patient retention in treatment at days 3 and 15 versus generic buprenorphine and Suboxone film respectively, as well as no increased rate of withdrawal symptoms or opioid cravings versus Suboxone film. The safety profile of ZUBSOLV was similar to that of Suboxone film.
MedicalResearch.com Interview with:
Carolyn J. Crandall, MD, MS
Professor of Medicine
David Geffen School of Medicine
UCLA Medicine/GIM
Los Angeles, California 90024
Medical Research: What is the background for this study? What are the main findings?
Dr. Crandall: In a large group of postmenopausal women aged 50-79, we found that women who reporting having hot flashes at baseline had increased risk of hip fracture during the subsequent 8 years of observation, nearly double the risk compared with women who did not have hot flashes at baseline.
MedicalResearch.com Interview with:
Brian I. Labow, MD
Director, Adolescent Breast Clinic
Assistant in Surgery Assistant Professor of Surgery
Harvard Medical School Primary
Medical Research: What is the background for this study? What are the main findings?
Dr. Labow: This study is part of our larger Adolescent Breast Disorder Study, in which we examine the impact of several breast disorders on adolescent girls and boys and measure the effect of treatment. In this present study we have found breast asymmetry, defined as having at least 1 cup size difference between breasts, can have a significant impact on the psychological wellbeing of adolescent girls. Validated surveys were given to adolescent girls with breast asymmetry, macromastia (enlarged breasts), and healthy unaffected girls between the ages of 12-21 to assess a wide array of health domains. Girls with breast asymmetry had noted deficits in psychological wellbeing and self-esteem when compared to healthy girls of the same age. These impairments were similar to those of girls with macromastia, a condition known to have significant negative mental health effects. Interestingly, these negative psychological outcomes did not vary by patient’s age or severity of breast asymmetry. Older and younger adolescents were negatively impacted similarly, as were those with lesser and greater degrees of breast asymmetry.
MedicalResearch.com Interview with:
Jeff Perry, MD, MSc, CCFP-EM
Associate Professor, Department of Emergency Medicine
Senior Scientist, Ottawa Hospital Research Institute
Research Chair in Emergency Neurological Research, University of Ottawa Emergency Physician, The Ottawa Hospital
Epidemiology Program, The Ottawa Hospital, Ottawa, Ontario
Medical Research: What is the background for this study? What are the main findings?
Dr. Perry: Currently it is not well known which patients with a TIA or a non-disabling stroke will have a subsequent stroke or die within the days to weeks following their initial event. This study found that patients with acute ischemia, especially if it is associated with an old infarction or microangiopathy, are at a much higher risk for an early subsequent stroke.
MedicalResearch.com Interview with:
Madhav Swaminathan, MBBS, MD, FASE, FAHA
Associate Professor with Tenure
Clinical Director, Division of Cardiothoracic Anesthesiology & Critical Care Medicine Department of Anesthesiology
Duke University Health System Durham, NC 27710
Medical Research: What is the background for this study? What are the main findings?
Dr. Swaminathan: The background is the need for salvage therapies for acute kidney injury (AKI,) which is a common complication in hospitalized patients. It is particularly a problem in the postoperative period after cardiac surgery. Preventive strategies have not worked well for decades. Hence the focus on strategies that target kidney recovery. Mesenchymal stem cells have been shown to be useful in enhancing kidney recovery in pre-clinical trials. We therefore hypothesized that administration of human Mesenchymal stem cells (AC607, Allocure Inc, Burlington, MA) to patients with established post-cardiac surgery AKI would result in a shorter time to kidney recovery. We conducted a phase 2, double blinded, placebo controlled, randomized clinical trial to test our hypothesis. Unfortunately we could not confirm the hypothesis and there were no significant differences in time to kidney recovery among patients that received AC607 versus placebo in 156 randomized cardiac surgery subjects.